Cancer involves a failure of the immune system in one of two ways:
- The immune system cannot recognize the tumor as foreign, or
- The immune response is shut down by the tumor
Replimune is pioneering a new class of oncolytic immunotherapy designed to ignite a powerful patient-specific immune response both locally at the site of the injected tumor and systemically throughout the body.
Our therapies are designed to not just treat a patient’s cancer, but also vaccinate against future relapse. Through oncolytic immunotherapy, we aim to both eradicate tumors today and prevent relapse in the future.
Ongoing Clinical Trials
Replimune has multiple ongoing clinical programs evaluating the safety and effectiveness of our investigational therapies in a range of solid tumors, both when given as single agents and in combination with other immunotherapies.